{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:25:24Z","timestamp":1793881524092,"version":"4.7.0"},"reference-count":42,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2026,10,3]]},"DOI":"10.1080\/14712598.2026.2736539","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T08:37:15Z","timestamp":1789807035000},"page":"1045-1057","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["An evaluation of denecimig for bleeding prophylaxis in hemophilia A"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5781-7669","authenticated-orcid":false,"given":"Johnny N.","family":"Mahlangu","sequence":"first","affiliation":[{"name":"University of the Witwatersrand","place":["Johannesburg, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,20]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2024.05.026"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000658"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803550"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102415"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14757"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010331"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15682"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2025.107162"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2517384"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-801662"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH17-01-0030"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137006"},{"key":"e_1_3_4_18_1","volume-title":"Presented at: Congress of the International Society on Thrombosis and Haemostasis","author":"Lund J","year":"2024","unstructured":"Lund J, Jensen K, Lillicrap D, et al. FVIII in vitro bioequivalence of Mim8\u00a0haemostatic effect by thrombin generation assays [oral presentation]. Presented at: Congress of the International Society on Thrombosis and Haemostasis; 2024 Jun 22\u201326; Bangkok, Thailand. Abstract OC 50.5."},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12794"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2023.12.016"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.102181"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2025.103207"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2026.104808"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2026.106914"},{"key":"e_1_3_4_25_1","volume-title":"Presented at: 34th Congress of the International Society on Thrombosis and Haemostasis","author":"Ong Clausen WH","year":"2026","unstructured":"Ong Clausen WH, Bovet J, Kreilgaard M. Tiered dosing with denecimig resulted in consistent steady-state exposure and bleed control in phase 3 frontier studies [poster]. Presented at: 34th Congress of the International Society on Thrombosis and Haemostasis; 2026 Jul 11\u201315; Paris, France. Poster PB2072."},{"key":"e_1_3_4_26_1","volume-title":"Presented at: European Association for Haemophilia and Allied Disorders Congress","author":"Weldingh K","year":"2024","unstructured":"Weldingh K, Pickering W, Robinson M, et al. FVIII inhibitors can be accurately determined in haemophilia a plasma in the presence of Mim8 [poster]. Presented at: European Association for Haemophilia and Allied Disorders Congress; 2024; Frankfurt, Germany. Poster PO007."},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2026.103472"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2026.103473"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-198617"},{"key":"e_1_3_4_30_1","volume-title":"Presented at: 33rd Congress of the International Society on Thrombosis and Haemostasis","author":"Mahlangu J","year":"2025","unstructured":"Mahlangu J, Ahuja S, Cockrell E, et al. Evaluating pen-injector handling and patient-reported outcomes in patients switching from emicizumab to Mim8 in FRONTIER5 [poster]. Presented at: 33rd Congress of the International Society on Thrombosis and Haemostasis; 2025; Washington, DC. Poster PB0812."},{"key":"e_1_3_4_31_1","volume-title":"Presented at: Congress of the International Society on Thrombosis and Haemostasis","author":"Kreilgaard M","year":"2024","unstructured":"Kreilgaard M, Lund J, Matytsina I. Higher thrombin generation is predicted when switching directly from emicizumab to Mim8 in patients with hemophilia A [poster]. Presented at: Congress of the International Society on Thrombosis and Haemostasis; 2024 Jun 22\u201326; Bangkok, Thailand. Poster PB0156."},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001869"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312611"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209226"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2216455"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027468"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014544.pub2"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00245-0"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2023.03.007"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14983"},{"key":"e_1_3_4_41_1","volume-title":"Presented at: 34th Congress of the International Society on Thrombosis and Haemostasis","author":"Kjalke M","year":"2026","unstructured":"Kjalke M, Lund J. Effects of denecimig and tranexamic acid in an in vitro clot-lysis assay [poster]. Presented at: 34th Congress of the International Society on Thrombosis and Haemostasis; 2026 Jul 11\u201315; Paris, France. Poster PB2093."},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025031894"},{"key":"e_1_3_4_43_1","unstructured":"ClinicalTrials.gov. A clinical study to evaluate the effects of NXT007 compared with factor VIII prophylaxis in people with hemophilia a (ZEBRHA 1). NCT07416526. [cited 2026 Sep 15]."},{"key":"e_1_3_4_44_1","unstructured":"ClinicalTrials.gov. A clinical study to evaluate the effects of NXT007 compared with emicizumab prophylaxis in people with hemophilia A (ZEBRHA 2). NCT07416604. [cited 2026 Sep 15]."}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2026.2736539","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14712598.2026.2736539","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2026.2736539","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:29:13Z","timestamp":1793878153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2026.2736539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,3]]}},"alternative-id":["10.1080\/14712598.2026.2736539"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2026.2736539","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-08-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}